{"title":"Pregnancy outcome following radioactive iodine therapy for Graves' disease in women of childbearing age: a systematic review.","authors":"Churun Xu, Lingge Wei, Peng Xie","doi":"10.1186/s13044-025-00242-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Graves' disease (GD) patients treated with radioactive iodine may face health risks from potential radiation exposure, both for themselves and their offspring. This systematic review aims to comprehensively evaluate the association between prior radioactive iodine (RAI) therapy for GD and subsequent pregnancy outcomes in women of childbearing age.</p><p><strong>Methods: </strong>A search of the bibliographic databases PubMed/MEDLINE and Web of Science was conducted up to December 2024 to identify relevant studies.</p><p><strong>Results: </strong>The final systematic review included 1055 patients from 5 articles, all of which were retrospective cohort studies. Two studies reported the incidence of miscarriage after RAI treatment of 2.3% (3/130) and 22.2% (6/27). One study indicated that the miscarriage rate in the RAI group was not significantly different from that in the control groups, while the other did not provide a statistical comparison between groups. Two studies reported the incidence of neonatal hyperthyroidism (NH) after RAI therapy of 11.3% (5/44) and 5.5% (8/145). Both studies indicated that high levels of serum TRAb during late pregnancy were significantly associated with NH (P < 0.05). One study reported the incidence of postpartum thyrotoxicosis (PT) after RAI therapy of 2.1%. Compared with surgical treatment and ATD treatment, patients with RAI therapy had a significantly lower incidence of PT (P < 0.05).</p><p><strong>Conclusion: </strong>Based on the limited evidence from retrospective studies, current data does not demonstrate a statistically significant increase in the risk of miscarriage or postpartum thyrotoxicosis following RAI therapy, compared to ATDs or surgical treatment. Elevated maternal TRAb levels in late pregnancy were strongly associated with neonatal hyperthyroidism. However, the small sample sizes and heterogeneity in study designs preclude definitive conclusions. Further prospective studies are required to establish more comprehensive and reliable conclusions and to evaluate more pregnancy outcomes.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"18 1","pages":"26"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12160348/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13044-025-00242-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Graves' disease (GD) patients treated with radioactive iodine may face health risks from potential radiation exposure, both for themselves and their offspring. This systematic review aims to comprehensively evaluate the association between prior radioactive iodine (RAI) therapy for GD and subsequent pregnancy outcomes in women of childbearing age.
Methods: A search of the bibliographic databases PubMed/MEDLINE and Web of Science was conducted up to December 2024 to identify relevant studies.
Results: The final systematic review included 1055 patients from 5 articles, all of which were retrospective cohort studies. Two studies reported the incidence of miscarriage after RAI treatment of 2.3% (3/130) and 22.2% (6/27). One study indicated that the miscarriage rate in the RAI group was not significantly different from that in the control groups, while the other did not provide a statistical comparison between groups. Two studies reported the incidence of neonatal hyperthyroidism (NH) after RAI therapy of 11.3% (5/44) and 5.5% (8/145). Both studies indicated that high levels of serum TRAb during late pregnancy were significantly associated with NH (P < 0.05). One study reported the incidence of postpartum thyrotoxicosis (PT) after RAI therapy of 2.1%. Compared with surgical treatment and ATD treatment, patients with RAI therapy had a significantly lower incidence of PT (P < 0.05).
Conclusion: Based on the limited evidence from retrospective studies, current data does not demonstrate a statistically significant increase in the risk of miscarriage or postpartum thyrotoxicosis following RAI therapy, compared to ATDs or surgical treatment. Elevated maternal TRAb levels in late pregnancy were strongly associated with neonatal hyperthyroidism. However, the small sample sizes and heterogeneity in study designs preclude definitive conclusions. Further prospective studies are required to establish more comprehensive and reliable conclusions and to evaluate more pregnancy outcomes.
目的:Graves病(GD)患者接受放射性碘治疗可能面临潜在辐射暴露的健康风险,无论是对他们自己还是他们的后代。本系统综述旨在全面评价育龄妇女先前放射性碘(RAI)治疗GD与随后妊娠结局之间的关系。方法:检索截至2024年12月的文献数据库PubMed/MEDLINE和Web of Science,确定相关研究。结果:最终的系统评价纳入了来自5篇文章的1055例患者,均为回顾性队列研究。两项研究报道RAI治疗后流产发生率分别为2.3%(3/130)和22.2%(6/27)。一项研究显示RAI组的流产率与对照组无显著差异,另一项研究未提供组间的统计学比较。两项研究报道RAI治疗后新生儿甲状腺功能亢进(NH)的发生率分别为11.3%(5/44)和5.5%(8/145)。结论:基于有限的回顾性研究证据,目前的数据并没有显示RAI治疗与ATDs或手术治疗相比,流产或产后甲状腺毒症的风险有统计学上的显著增加。妊娠后期母体TRAb水平升高与新生儿甲状腺功能亢进密切相关。然而,小样本量和研究设计的异质性妨碍了明确的结论。需要进一步的前瞻性研究来建立更全面和可靠的结论,并评估更多的妊娠结局。